Zevra Therapeutics, Inc. Repayments of Debt
Zevra Therapeutics, Inc. (ZVRA) reported Repayments of Debt of $60.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2026-08-05
- Zevra Therapeutics, Inc. repayments of debt for the quarter ending 2026-06-30 was $0.00.
- Zevra Therapeutics, Inc. repayments of debt for the quarter ending 2026-03-31 was $60.09M.
- Zevra Therapeutics, Inc. repayments of debt for the quarter ending 2025-12-31 was $0.00.
- Zevra Therapeutics, Inc. repayments of debt for the quarter ending 2025-09-30 was $0.00.
- Zevra Therapeutics, Inc. repayments of debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Zevra Therapeutics, Inc. repayments of debt for fiscal 2024 was $42.70M, a 143.57% increase from fiscal 2023.
- Zevra Therapeutics, Inc. repayments of debt for fiscal 2023 was $17.53M.
- Zevra Therapeutics, Inc. repayments of debt for fiscal 2022 was $0.00.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $60.09M 10-Q · filed 2026-08-05 | $60.09M derived: sum of 3 quarters · filed 2026-08-05 | $60.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $60.09M 10-Q · filed 2026-05-06 | $60.09M derived: sum of 2 quarters · filed 2026-05-06 | $60.09M derived: sum of 3 quarters · filed 2026-05-06 | $60.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $42.70M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $42.70M derived: sum of 3 quarters · filed 2026-03-09 | $42.70M 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $42.70M derived: sum of 2 quarters · filed 2025-11-05 | $42.70M 10-Q · filed 2025-11-05 | $47.43M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $42.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $42.70M 10-Q · filed 2025-08-12 | $47.43M derived: sum of 3 quarters · filed 2025-08-12 | $47.22M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $4.73M derived: sum of 2 quarters · filed 2025-03-12 | $4.52M derived: sum of 3 quarters · filed 2025-03-12 | $4.73M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-12-31 | $4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $4.52M derived: sum of 2 quarters · filed 2025-03-12 | $4.73M derived: sum of 3 quarters · filed 2025-03-12 | $17.53M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$207.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $12.80M 10-Q · filed 2024-11-13 | $12.80M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $207.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $13.01M 10-Q · filed 2024-08-14 | $13.01M derived: sum of 3 quarters · filed 2024-08-14 | $13.01M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $12.80M 10-Q · filed 2024-05-09 | $12.80M derived: sum of 2 quarters · filed 2024-05-09 | $12.80M derived: sum of 3 quarters · filed 2024-05-09 | $12.80M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | $0.00 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |